Randox supports Health Secretary’s new 21st century focus on prevention
For over 36 years, Randox has been developing cutting-edge diagnostic technologies to improve the quality, accuracy and timeliness of laboratory results, because we firmly believe that access to accurate and timely diagnostics is key to improving healthcare.
As 70% of clinical decisions are based on laboratory output, our efforts are central to healthcare and improving patient outcomes. It will come as no surprise therefore that we support the announcement made by Health Secretary Matt Hancock this week about a new green paper, entitled “Prevention is better than cure,” that will argue for a shift towards preventative healthcare, to help people stay well.
On Monday Mr Hancock argued that the “numbers don’t stack up” when it comes to spending on prevention as opposed to treatment, with £97bn of public money in the UK spent on treating disease and only £8bn preventing it.
He added that “we need a new 21st century focus on prevention.”
Duncan Selbie, Chief Executive Public Health England, echoed Mr Hancock’s sentiments by saying; “We need to move from a system that detects and treats illnesses to one that also predicts and prevents poor health through promoting health in all policies and puts people back in charge of their own health.”
It’s a goal that we at Randox share with both Mr Hancock and Mr Selbie. With new and emerging diagnostic technologies, we can speed up diagnoses, improve patient outcomes, make every pound go further and give clinicians more time with their patients.
Much earlier and much more effective diagnosis can simultaneously improve healthcare outcomes and reduce the burden on healthcare services.
At Randox, we look forward to a time when sickness is actively prevented, rather than managed. By utilising innovative diagnostic products capable of diagnosing disease and ill-health at the earliest possible stage, we can truly transform the life of the patient.
For further information please email email@example.com
Biochip Array Technology
In 1992, Randox invested £180 million to create and introduce Biochip Array Technology (BAT) which converted laboratory testing. Randox came up with the innovation by recognising the major problem with traditional diagnosis. Within traditional diagnosis several tests are typically required which involves multiple blood draws from the patient, many visits to the hospital, increased reagent volume and increased time to diagnosis. Biochip Array Technology allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from one single sample. Therefore, it is faster, cost saving and more effective leading to better clinical decisions. Today the technology (BAT) is used in countless laboratories worldwide and a range of three biochip analysers are now offered.
The main basis of the Biochip Array Technology
- 9x9mm biochip which acts as a solid phase reaction vessel.
- Each of the biochips are pre-coated with an array of discrete test regions (DTRs)
- One biochip per sample used to generate multiple results.
- Randox Biochips hold up to 49 tests.
- Based on chemiluminescent signal emitting light, without heat which results a chemical reaction.
The key features and benefits of the Biochip Array Technology
Highly accurate testing
- The biochip array technology provides high standard of accurate test results with CV’s <10%
- Multiplex analysis minimises analytical variation between the tests.
- Increased patient information available through testing multiple markers
- Patients receive their results quicker compared to the traditional diagnosis.
Reduced sample volume
- Reduced sample required therefore patients feel more at ease.
Wide test menu
- Wide test menu provides a variety for clients and allows flexibility.
- Multiple samples can be used on BAT which include the following; serum, plasma, whole blood, urine and many others which allows for flexibility in their testing
– The process reduces the amount of time spent on individual tests and associated laboratory costs
Biochip testing platforms
The Evidence Evolution is fully automated random-access biochip testing platform. The machine allows any test to perform at any time as it is a highly versatile analyser which can operate any workflow. It can receive 2640 tests per hour which means the machine has a fast turnaround time. As well as this, it allows multiple tests to be performed from a single sample which reduces time and resources spent on individual tests. The Evidence Evolution can be tailored to certain laboratory needs and have features including automatic start-up and shut down, relaxed testing capability and traceability of biochips. The equipment overall is made to be easy for the client to use as it includes customisable user settings and easy to follow result screens giving them the fast and accurate operations they would prefer.
The Evidence Analyser is the protein Biochip Array technology. Like the Evidence Evolution it is fully automated which is suitable for busy laboratories, hospitals, forensic and clinical toxicology. The machine is floor standing and can receive up to 3690 per hour. The machine has features such as easy to follow software and customisable user settings which gives laboratories the opportunity to receive fast and accurate results.
The Evidence Investigator is often used for research, clinical, forensic, molecular and veterinary testing. The machine is semi-automated and can combine immunoassay and molecular diagnostics on a single platform with protein and DNA biochips. This machine also has a quick turnaround time with the ability to achieve 2376 tests per hour with 44 analytes screened per biochip. The evidence investigator provides more tests on the test menu which allows variety.
The final platform is the Evidence MultiSTAT. The Evidence MultiSTAT is a fully-automated analyser which provides quality results. It is a simple and easy to use analyser which requires minimal training with only three steps to complete the process. The machine can provide multiplex testing yields up to 46 results in under ten minutes. It is ease-of-use for non-laboratory staff and provides full traceability of user action with password controlled software.
Having developed the patented Biochip Array Technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series.
The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the overview of each analyser in the Evidence Series
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
You visit the doctor because you think there is a problem. The doctor suspects it may be an infection but she’s not sure. A blood sample is taken and sent to the laboratory where three to five tests are run on it. Your blood does not show a positive reading for any of the tests conducted. You still don’t know what’s wrong. Does this sound familiar?
Enter a pioneering piece of technology called the Biochip. This health testing platform, from global diagnostics company Randox, and on show at this year’s Goodwood Festival of Speed, can currently run 49 different tests simultaneously – making sure you get the right diagnosis as fast as possible.
Current and futuristic developments in this critical strand of medicine, involving detailed analysis of blood to identify both current and future health risks, are appearing as part of the festival’s Future Lab project. Those visiting Future Lab will learn how technology can be utilised to improve the speed and accuracy of health diagnoses across the world.
With further plans to expand and enhance the Biochip even further – with capabilities to run over 1024 tests on a single blood sample – this technology is set to revolutionise the future of healthcare.
Randox Founder and Managing Director, Dr Peter FitzGerald, commented;
“For years we’ve been working behind-the-scenes with hospitals and laboratory professionals and, until now, our contribution to improving healthcare would not have been evident to the general public. But we know now that it’s time for us to come out – our technologies have the potential to transform healthcare around the world, and that matters to everyone.
“More sensitive, comprehensive and accurate technologies hold the promise of much earlier and effective diagnosis, often before symptoms appear – greatly improving healthcare outcomes and reducing the burden on healthcare services. And these technologies are directly available to the individual through our consumer division Randox Health, not just through GPs or hospitals.
“It is also a fact that diagnostics have historically been undervalued – in healthcare systems around the world laboratory technologies account for around 2% of overall budgets, yet 70%-80% of all healthcare decisions affecting diagnosis or treatment involve a laboratory investigation.”
Sensing the potential to improve healthcare through diagnostic innovation, Randox has invested significantly in the development of Biochip Array Technology, allowing many tests to be run simultaneously.
Dr FitzGerald continued;
“It’s taken over £285 million to see the fruition of this, the gold standard in testing. Our 300-strong team of research scientists and engineers are committed to exploring the thousands of markers of health and illness within the body and to each year unveil pioneering and innovative new tests to add to the Randox portfolio. Thanks to an annual investment of around 16% of turnover in this research and development, we have more innovations in development than any other healthcare company in the world.”
One such innovation, the concept of which is due to be revealed at the Goodwood Future Lab for the first time, is the unrivalled 32×32 Biochip. This highly anticipated testing platform will remarkably be able to provide patients with 1024 key pieces of information about their current and future health. Combined with advanced algorithms, the effect will be truly revolutionary.
Dr FitzGerald added;
“The 32×32 Biochip is key to unlocking true personalised medicine. Ultimately it acts as a roadmap of your health by predicting the health conditions of which you are personally at risk in the future. By taking preventive action you will be empowered to live healthier for longer. It’s the world’s first technology of its kind, capable of extending your life.”
The Randox Health Mobile Clinic, in which the public can directly access Randox technologies in the form of the world’s most comprehensive health check, will be at the Goodwood Hotel on Tuesday 17th and Wednesday 18th July. Those wishing to book can call 0800 2545 130 or can find out more by visiting the Randox Health website or downloading the app.
For further information please contact Randox PR by email: firstname.lastname@example.org or by phoning 07980 738 120
Diagnostic engineering company, Randox Teoranta, has been officially announced as the main sponsor of the Engineering Technology Teachers’ Association (ETTA) conference. Randox Teoranta, based in Donegal’s coastal town Dungloe, is the global diagnostic company’s hub for world-leading engineering and life sciences in the west of Ireland.
Randox Teoranta’s sponsorship of the renowned ETTA awards comes as it aims to attract Ireland’s top engineers and scientists to join the team which is based in its next-generation life science, engineering, research and manufacturing centre in Donegal.
The company is recognised globally for its commitment to improving healthcare and technology, and in the past year alone scientists and engineers at Randox Teoranta have developed a revolutionary test for Alzheimer’s disease, designed drug testing software to be used by police officers in criminal investigations, and engineered new technologies with the ability to detect disease and save lives. The team is currently working on cutting-edge research for key health issues including kidney disease, thyroid disease and gastrointestinal disorders.
ETTA is a voluntarily administered association which represents teachers of Engineering Technology and Metalwork. Its focus is to promote technology as an exciting career choice for young people, providing a National Engineering Awards programme for second level students. It works in conjunction with Engineers Ireland, third level colleges and the Department of Education to ensure the highest standards of Engineering Technology education.
In attendance on the launch evening in the Letterkenny Institute of Technology were Christina Mc Fadden, Breid Gallagher and Daniel Melly representing Randox Teoranta; Denis Mc Fadden and Jim Morrison from LYIT; and Dr. Martin Gormley, Director of Schools in Donegal ETB. There was also an excellent turnout from branch members on the night.
Chairperson of the Donegal Branch of the ETTA, Sean Mc Fadden said,
“We would like to acknowledge Randox Teoranta and express our sincere thanks on becoming the main sponsors for the ETTA National Conference 2017, bringing their wealth of knowledge, resources and expertise in the field of engineering to the table. Randox has been bringing high-end engineering employment to Donegal since it opened and are always enthusiastic to develop links with the Education sector here. The expansion of Randox Teoranta is an exciting prospect for many of our students with world-class engineering and technology now right on their doorstep.”
Christina Mc Fadden, Engineering Manager at Randox Teoranta said:
“We’re delighted to support these awards which honour the very best engineering students in Ireland. Randox’s success owes a great deal to our team of engineers who hold a prestigious MacRobert Award and are constantly driving new innovations that transform patients’ lives around the world. Since opening our R&D and manufacturing centre in Dungloe in 2010, we’ve provided unrivalled opportunities to mechanical, software and electrical engineers. We are committed to encouraging more people to see engineering as a viable career option, and then to ensure our very talented students are able to pursue outstanding careers here on this island.”
The ETTA Conference and Awards Ceremony will be hosted by Letterkenny Institute of Technology (LYIT) on Friday 17th and Saturday 18th November 2017.
For further information about the Randox Teoranta sponsorship of the ETTA Awards, please contact Randox PR by phoning 028 9445 1016 or emailing RandoxPR@randox.com
As an international organisation that aims to deliver world class pioneering research that will revolutionise healthcare worldwide, we are always pleased when the next generation of scientists want to come and visit us. So we were delighted when Ballymacrickett Primary School got in touch with us to organise a visit.
Last week Randox welcomed primary 7 pupils from Ballymacricket Primary School to our Randox labs to gain a first class insight into the work that we carry out here. As part of the collaboration Randox is sponsoring Ballymacrickett Primary School to conduct their very own STEM project that will allow primary 7 pupils to take part in the Junior Innovators project. This project is run alongside Sentinus, a non-profit educational charity that works with schools throughout Northern Ireland to deliver programs to promote engagement in STEM subjects.
As part of the project the primary 7 pupils will conduct cross circular project work which can include workbooks, exhibition materials, models of products and even the development of a mini enterprise and their very own products. The aim of this project is to support the development of links between primary schools and local business and industry and to give classroom learning relevance to the world of work through a structured program of activity.
The first step in the project involves a visit to a local company, and we were thrilled to welcome over 50 pupils to our headquarters here in Crumlin from the 24th-27th October. The tour included a visit around our different departments and behind the scenes access to our science labs to gain a better insight into the work that we pioneer which was especially interesting.
At the end of the tour each pupil received a goodie bag filled with plenty of Randox stationery to take back to school with them.
We are delighted that the tour was both enjoyable and informative and sparked an interest in many more pupils to enter the world of science!
Good luck Ballymacrickett Primary School- We can’t wait to see your final project!
Make sure to follow Randox Careers on Facebook, Twitter and Instagram to stay up-to-date with the hashtag #WeAreRandox
We’re sure you’ve heard of “Speed Dating”, but what about “Speed Networking”? Randox’s R&D Scientist, Dr. Dwaine Vance tried it out to spread the word about Randox Careers in STEM!
Dr Dwaine Vance visited Omagh High School to represent Randox Careers. He sat down with us, and we discussed the importance of the event. Dr. Vance told us:
On Wednesday the 15th June I represented Randox Careers at a ‘speed networking’ event at Omagh High School. This involved groups of students moving from one employer stand to the next for a 5 minute ‘mini network’. There was two sessions during the morning involving GCSE level pupils. The aim of the ‘speed networking’ event was to provide pupils with opportunities to meet local Northern Irish companies within the Science, Technology, Engineering and Mathematics (STEM) sectors, of which Randox Laboratories play a pivotal role.
We, at Randox, want to inspire students to think about their own career plans and to allow them to gather information about the local job market. By doing this, we’re also giving them the opportunity to be aware of the jobs that are available and the importance of STEM related subjects, as well as letting them see how employers value their other curriculum subjects and their personal skills and attributes. My objective as a employee of Randox was to showcase a range of careers for all abilities within the company with a focus on STEM careers e.g. science and engineering.
The importance of spreading awareness of the opportunities in science and engineering from a young age is imperative, as many students are unaware of the vast range of differentiation in different careerpaths, stemming from one subject or degree class. Dr. Dwaine Vance went on to discuss the events of the networking conference:
As part of each ‘mini network’ I provided students with a brief overview of Randox. Students were given the opportunity to watch videos depicting our expertise and to ask questions about how their interests could be incorporated within Randox. The training department at Randox provided me with pop-up stands, recruitment pathway brochures, merchandise e.g. pens, stopwatches, mug coasters and even Biochip Array Technology key rings!
Overall the students gained a good knowledge of Randox, they were particularly keen to learn about the local and global opportunities available at Randox. In addition, students were keen to know more about the veterinary aspect of Randox. It was comforting to discover that the majority of pupils had previous knowledge of the Randox brand from the press (as we have recently experienced a great boost in brand visibility through Grand national sponsorship), Randox health (television adverts) and Confidante (local radio stations).
The pupils at Omagh High School were keen to ask me about my role within the company and what my day to day roles and responsibilities are. I was happy to provide students with my research and development activities and they were interested to hear that I was involved in the development of a genetic test that aims to predict your future risk of heart disease by investigating your own DNA.
At Randox I am part of a small team of experienced research scientists that are developing a genetic risk prediction test for heart disease and myocardial infarction. This test aims to simultaneously genotype 20 genetics variants that have been previously associated with increased risk of heart disease. This Randox molecular test is in collaboration with leading University academics and will help reduce the burden of heart disease throughout the world by providing an accurate risk assessment of disease so personalised treatment can be provided to those who require it most. To quote Randox Health, “Prevention is better than cure”.
From everyone at the Randox Careers team and from Dr. Dwaine Vance, we’d like to thank Omagh High School for inviting us to attend this incredibly beneficial Speed Networking event, where we feel we have truly impacted the young minds of tomorrow. We look forward to the future of diagnostics, with you!